Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Santen Pharmaceutical and Inspire Pharmaceuticals have reported that the Japanese Ministry of Health, Labour and Welfare has granted approval for the new dry eye treatment drug Diquas Ophthalmic Solution 3% (generic name: diquafosol tetrasodium) on 16 April 2010.
Subscribe to our email newsletter
Diquafosol was licensed for certain ophthalmic uses from Inspire and Diquas Ophthalmic Solution 3% was developed by Santen as a treatment for dry eye.
Reportedly, in clinical studies conducted in Japan, Diquas Ophthalmic Solution 3% was shown to improve dry eye symptoms by promoting secretion of mucin and water, thereby bringing the tear film closer to a normal state. In addition, no serious ocular or systemic adverse drug reactions were found during the clinical trials.
Santen currently markets ‘Hyalein Ophthalmic Solution 0.1%’ and several other dry eye treatment products. The addition of ‘Diquas Ophthalmic Solution 3%’ to the Santen product lineup is expected to increase treatment choices for medical professionals, and contribute to improving QOL (quality of life) for dry eye patients.